Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Pyxis Oncology Inc (PYXS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.61-3.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PYXS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Extend cash runway into Q4 2026 | It aims to extend cash into Q4 2026. | Intact | Cash runway does not extend into Q4 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development story, not an established earnings compounder. The thesis is still developing: MICVO has shown early clinical progress, but confidence in the broader investment case is low.
The evidence labels pricing as justified and reports no signs of unusual fragility, but it does not provide peer valuation details or a clear market-expectations benchmark. The expectations-gap measure is negative, so the evidence does not support a claim that the market has priced in an easy path to success.
Near term, the company remains loss-making, recent financial performance is weak, and the next-quarter earnings-miss risk is elevated. Management has reported positive Phase 1 MICVO data and plans to start a pivotal Phase 3 trial in mid-2027, while financing extended the stated cash runway into Q2 2027; expense control remains mixed.
The multi-year thesis depends on whether MICVO's early results lead to successful later-stage development and whether the planned Phase 3 start happens on schedule. Near term, a guidance cut, continued weakness in employment data, or better results from healthcare peers could affect the operating backdrop; litigation and debt issuance are also recent events, though their impact is not detailed here.
Over the next 1 to 3 years, PYXS remains a high-risk, watch-stage clinical story: meaningful trial progress is offset by weak financial performance, limited runway, and low overall confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Pyxis is developing a new cancer drug called MICVO. |
| Improving |
| Development of MICVO stalls or fails to advance |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize or grow revenue after expected decline | A supporting condition in Pyxis Oncology Inc's published investment case. The stated target is Revenue growth better than -18% in next 12 months. | Intact | Revenue declines worse than -18% over next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.21 → $-1.11 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-25 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-26 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-27 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-28 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-29 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-30 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-07-31 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-01 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-02 | $-1.21 | $3,125,000 | 8 / 8 |
| 2026-08-03 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-04 | $-1.21 | $3,125,000 | 8 / 8 |
| 2026-08-05 | $-1.21 | $3,125,000 | 8 / 8 |
| 2026-08-06 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-07 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-08 | $-1.20 | $2,777,780 | 9 / 9 |
| 2026-08-09 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-10 | $-1.20 | $2,777,780 | 9 / 9 |
| 2026-08-12 | $-1.20 | $2,777,780 | 9 / 9 |
| 2026-08-13 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-14 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-15 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-16 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-17 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-18 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-19 | $-1.21 | $4,166,667 | 6 / 8 |
| 2026-08-20 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-21 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-22 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-23 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-24 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-25 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-26 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-27 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-28 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-29 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-30 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-08-31 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-01 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-02 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-03 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-04 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-05 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-06 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-07 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-08 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-09 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-10 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-11 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-12 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-13 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-14 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-15 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-16 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-17 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-18 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-19 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-20 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-21 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-22 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-23 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-24 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-25 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-26 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-27 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-28 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-29 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-09-30 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-01 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-02 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-03 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-04 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-05 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-06 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-07 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-08 | $-1.13 | $3,125,000 | 6 / 9 |
| 2026-10-09 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-10 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-11 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-12 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-13 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-14 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-15 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-16 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-17 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-18 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-19 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-20 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-21 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-22 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-23 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-24 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-25 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-26 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-27 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-28 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-29 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-30 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-10-31 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-11-01 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-11-02 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-11-03 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-11-04 | $-1.11 | $3,125,000 | 6 / 9 |
| 2026-11-05 | $-1.11 | $3,125,000 | 6 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.